Ambit Biosciences Receives $30,000,000 Series D Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f1d5c08a-248e-4748-869e-1f8a9ea43a5a&Preview=1
Date 6/10/2011
Company Name Ambit Biosciences
Mailing Address 4215 Sorrento Valley Blvd. San Diego, CA 92121
Company Description Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer.
Proceeds Purposes This recent capital raise will allow us to continue the clinical development of our lead product candidate, AC220, which is currently in a Phase 2 pivotal trial in Acute Myeloid Leukemia. This financing also provides for the continued development of our other two clinical assets, AC430 and AC480, both of which are in Phase 1 trials.